Cargando…
Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text]
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711218/ https://www.ncbi.nlm.nih.gov/pubmed/34964016 http://dx.doi.org/10.1002/agm2.12179 |